^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Cholesterol absorption inhibitor

    Related drugs:
    15d
    Ezetimibe Normalizes Dietary Cholesterol-Induced Exacerbation of Liver Injury in Alcohol-Fed Mice. (PubMed, Biomolecules)
    Moreover, mice fed a diet containing both cholesterol and alcohol exhibited increased expression of monocyte chemoattractant protein 1 (Mcp1) and tumor necrosis factor alpha (Tnfα) in the distal small intestine. Collectively, our findings indicate that ezetimibe effectively mitigates the adverse effects of dietary cholesterol and alcohol consumption on hepatic lipid accumulation and liver injury.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CCL2 (Chemokine (C-C motif) ligand 2)
    20d
    Investigation of the nitric oxide signaling pathway induced by ezetimibe on renal injury in streptozotocin-induced diabetic rat: role of anti-oxidative and anti-inflammatory effects. (PubMed, Immunopharmacol Immunotoxicol)
    Sixty rats were used in the study, divided into the following groups: a control group (healthy rats), a diabetic control group, a diabetic group treated with metformin, a diabetic group treated with ezetimibe, a diabetic group treated with ezetimibe plus L-NAME, and a diabetic group treated with ezetimibe plus L-arginine. However, the beneficial effects of ezetimibe were reversed by L-NAME. Ezetimibe protected the kidney against diabetic injury mainly by activating the nitric oxide signaling pathway, enhancing antioxidant enzyme activity, and reducing inflammation, suggesting that its nephroprotective effects are NO-dependent.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CAT (Catalase)
    |
    metformin
    1m
    SPECTRE: Towards an Effective Treatment for Heart Complications After Surgery (feasibility study) (ACTRN12626000464369)
    P=N/A, N=60, Not yet recruiting, Melbourne Health
    New trial
    1m
    Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD (clinicaltrials.gov)
    P=N/A, N=1952, Not yet recruiting, Yonsei University
    New trial
    1m
    PIVOT: Efficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study (clinicaltrials.gov)
    P=N/A, N=10000, Recruiting, JW Pharmaceutical
    New trial
    |
    pitavastatin
    1m
    The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells. (PubMed, Oncotarget)
    Knock down of SCD1 enhanced the percentage of dead cells in vehicle control treated cells but did not alter the abilities of drugs to kill tumor cells. Our data demonstrates that UM cells are killed by treatment with aramchol plus regorafenib plus metformin via enhanced autophagic flux and that this combination may have the potential to control UM tumors that have metastasized to the liver.
    Journal
    |
    ATG5 (Autophagy Related 5) • BECN1 (Beclin 1) • LAMP2 (Lysosomal Associated Membrane Protein 2) • SCD (Stearoyl-CoA Desaturase)
    |
    Stivarga (regorafenib) • metformin • Aramchol (aramchol meglumine)
    2ms
    Musashi: A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia (clinicaltrials.gov)
    P=N/A, N=2560, Active, not recruiting, Daiichi Sankyo | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    2ms
    Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet (clinicaltrials.gov)
    P1, N=32, Recruiting, Galmed Pharmaceuticals Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Aramchol (aramchol meglumine)
    2ms
    Ezetimibe counteracts lipopolysaccharide-induced liver injury in mice via modulating TLR4-mediated MYD88/TRAF-6/NF-kB signaling pathway. (PubMed, Toxicol Appl Pharmacol)
    Additionally, myeloid differentiation primary-response protein 88 (MYD88), TNF Receptor Associated Factor 6 (TRAF-6) and IL-6 were markedly reduced in the liver by EZE. Collectively, EZE may be a promising candidate in sepsis-related liver injury following further clinical studies.
    Preclinical • Journal • IO biomarker
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • TLR4 (Toll Like Receptor 4) • TRAF6 (TNF Receptor Associated Factor 6)
    3ms
    Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia (clinicaltrials.gov)
    P=N/A, N=6927, Completed, JW Pharmaceutical
    New trial
    |
    pitavastatin
    3ms
    Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides (clinicaltrials.gov)
    P4, N=88, Active, not recruiting, JW Pharmaceutical
    New P4 trial
    |
    pitavastatin
    3ms
    Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial (clinicaltrials.gov)
    P=N/A, N=4400, Not yet recruiting, Yonsei University
    New trial